Uncovering the genomic heterogeneity of multifocal breast cancer

Journal of Pathology

Volumn 236, Issue 4, 2015, Pages 457-466

  Desmedt, Christine ^a   Fumagalli, Debora ^a   Pietri, Elisabetta ^b   Zoppoli, Gabriele ^a,c   Brown, David ^a   Nik Zainal, Serena ^d   Gundem, Gunes ^d   Rothé, Françoise ^a   Majjaj, Samira ^a   Garuti, Anna ^c   Carminati, Enrico ^c   Loi, Sherene ^a,e   Van Brussel, Thomas ^f   Boeckx, Bram ^f   Maetens, Marion ^a   Mudie, Laura ^d   Vincent, Delphine ^a   Kheddoumi, Naima ^a   Serra, Luigi ^g   Massa, Ilaria ^b   Ballestrero, Alberto ^c   Amadori, Dino ^b   Salgado, Roberto ^a,h   De Wind, Alexandre ^a   Lambrechts, Diether ^f   Piccart, Martine ^a   Larsimont, Denis ^a   Campbell, Peter J ^d,i,j   Sotiriou, Christos ^a   more..

^a JULES BORDET INSTITUTE   (Belgium)

^b DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g MORGAGNI PIERANTONI HOSPITAL   (Italy)

^h Breast International Group (BIG)   (Belgium)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j ADDENBROOKE S HOSPITAL   (United Kingdom)

more..

Author keywords

breast cancer; genomic heterogeneity; multicentric; multifocal; oncogenic mutations; targeted sequencing

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4 PHOSPHATE 3 KINASE; PROTEIN P53; TRANSCRIPTION FACTOR GATA 3; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIPLE CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR GENE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; BREAST TUMOR; CANCER GRADING; CHEMISTRY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; INTRADUCTAL CARCINOMA; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PAGET NIPPLE DISEASE; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASMS, MULTIPLE PRIMARY; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84937518723     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4540     Document Type: Article

References (40)

1. Salgado R, Aftimos P, Sotiriou C, et al., Evolving paradigms in multifocal breast cancer. Semin Cancer Biol 2015; 31: 111-118.
2. Lynch SP, Lei X, Chavez-Macgregor M, et al., Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 2012; 23: 3063-3069.
3. Wolters R, Wöckel A, Janni W, et al., Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients. Breast Cancer Res Treat 2013; 142: 579-590.
4. Tot T., Early and more advanced unifocal and multifocal breast carcinomas and their molecular phenotypes. Clin Breast Cancer 2011; 11: 258-263.
5. Bendifallah S, Werkoff G, Borie-Moutafoff C, et al., Multiple synchronous (multifocal and multicentric) breast cancer: clinical implications. Surg Oncol 2010; 19: e115-123.
6. Pedersen L, Gunnarsdottir KA, Rasmussen BB, et al., The prognostic influence of multifocality in breast cancer patients. Breast 2004; 13: 188-193.
7. Cabioglu N, Ozmen V, Kaya H, et al., Increased lymph node positivity in multifocal and multicentric breast cancer. J Am Coll Surg 2009; 208: 67-74.
8. Vlastos G, Rubio IT, Mirza NQ, et al., Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. Ann Surg Oncol 2000; 7: 581-587.
9. Joergensen LE, Gunnarsdottir KA, Lanng C, et al., Multifocality as a prognostic factor in breast cancer patients registered in Danish Breast Cancer Cooperative Group (DBCG) 1996-2001. Breast 2008; 17: 587-591.
10. Litton JK, Eralp Y, Gonzalez-Angulo AM, et al., Multifocal breast cancer in women < or =35 years old. Cancer 2007; 110: 1445-1450.
11. Leopold KA, Recht A, Schnitt SJ, et al., Results of conservative surgery and radiation therapy for multiple synchronous cancers of one breast. Int J Radiat Oncol Biol Phys 1989; 16: 11-16.
12. Yerushalmi R, Kennecke H, Woods R, et al., Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Res Treat 2009; 117: 365-370.
13. Pekar G, Hofmeyer S, Tabár L, et al., Multifocal breast cancer documented in large-format histology sections: long-term follow-up results by molecular phenotypes. Cancer 2013; 119: 1132-1139.
14. Lester SC, Bose S, Chen YY, et al., Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med 2009; 133: 1515-1538.
15. Buggi F, Folli S, Curcio A, et al., Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all individual foci justified? Ann Oncol 2012; 23: 2042-2046.
16. Choi Y, Kim EJ, Seol H, et al., The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumour foci in multifocal/multicentric invasive ductal carcinoma of breast. Hum Pathol 2012; 43: 48-55.
17. Pekar G, Gere M, Tarjan M, et al., Molecular phenotype of the foci in multifocal invasive breast carcinomas: intertumoural heterogeneity is related to shorter survival and may influence the choice of therapy. Cancer 2014; 120: 26-34.
18. Varela I, Tarpey P, Raine K, et al., Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469: 539-542.
19. Ye K, Schulz MH, Long Q, et al., Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 2009; 25: 2865-2871.
20. Wang L, Yamaguchi S, Burstein MD, et al., Novel somatic and germline mutations in intracranial germ cell tumours. Nature 2014; 511: 241-245.
21. Papaemmanuil E, Gerstung M, Malcovati L, et al., Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616-3627.
22. Campbell PJ, Yachida S, Mudie LJ, et al., The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-1113.
23. Stephens PJ, McBride DJ, Lin ML, et al., Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009; 462: 1005-1010.
24. Scheinin I, Sie D, Bengtsson H, et al., DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Res 2014; 24: 2022-2032.
25. Nilsen G, Liestøl K, Van Loo P, et al., Copynumber: efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics 2012; 13: 591.
26. Carter SL, Cibulskis K, Helman E, et al., Absolute quantification of somatic DNA alterations in human cancer. Nature Biotechnol 2012; 30: 413-421.
27. Schwarz RF, Trinh A, Sipos B, et al., Phylogenetic quantification of intra-tumour heterogeneity. PLoS Comput Biol 2014; 10: e1003535.
28. Zack TI, Schumacher SE, Carter SL, et al., Pan-cancer patterns of somatic copy number alteration. Nature Genet 2013; 45: 1134-1140.
29. Zardavas D, Maetens M, Irrthum A, et al., The AURORA initiative for metastatic breast cancer. Br J Cancer 2014; 111: 1881-1887.
30. Eeles R, Knee G, Jhavar S, et al., Multicentric breast cancer: clonality and prognostic studies. Breast Cancer Res Treat 2011; 129: 703-716.
31. Dawson PJ, Baekey PA, Clark RA,. Mechanisms of multifocal breast cancer: an immunocytochemical study. Hum Pathol 1995; 26: 965-969.
32. Noguchi S, Aihara T, Koyama H, et al., Discrimination between multicentric and multifocal carcinomas of the breast through clonal analysis. Cancer 1994; 74: 872-877.
33. Teixeira MR, Ribeiro FR, Torres L, et al., Assessment of clonal relationships in ipsilateral and bilateral multiple breast carcinomas by comparative genomic hybridisation and hierarchical clustering analysis. Br J Cancer 2004; 91: 775-782.
34. Tsuda H, Hirohashi S,. Identification of multiple breast cancers of multicentric origin by histological observations and distribution of allele loss on chromosome 16q. Cancer Res 1995; 55: 3395-3398.
35. Harvey JM, Clark GM, Osborne CK, et al., Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
36. Leake R, Barnes D, Pinder S, et al., Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol 2000; 53: 634-635.
37. Wolff AC, Hammond ME, Schwartz JN, et al., American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
38. Elston CW, Ellis IO,. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
39. Genestie C, Zafrani B, Asselain B, et al., Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems. Anticancer Res 1998; 18: 571-576.
40. Nik-Zainal S, Van Loo P, Wedge DC, et al., The life history of 21 breast cancers. Cell 2012; 149: 994-1007.